Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 341

1.

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD.

Voorham J, Corradi M, Papi A, Vogelmeier CF, Singh D, Fabbri LM, Kerkhof M, Kocks JH, Carter V, Price D.

ERJ Open Res. 2019 Aug 30;5(3). pii: 00106-2019. doi: 10.1183/23120541.00106-2019. eCollection 2019 Jul.

2.

ERS/EAACI Statement on severe exacerbations in asthma in adult: facts, priorities and key research questions.

Bourdin A, Bjermer L, Brightling C, Brusselle G, Chanez P, Chung F, Custovic A, Diamant Z, Diver S, Djukanovic R, Hamerlijnck D, Johnston S, Kanniess F, Papadopoulos N, Papi A, Russell R, Ryan D, Samitas K, Tonia T, Zervas E, Gaga M.

Eur Respir J. 2019 Sep 12. pii: 1900900. doi: 10.1183/13993003.00900-2019. [Epub ahead of print]

PMID:
31467120
3.

Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary disease.

Pascoe SJ, Papi A, Midwinter D, Lettis S, Barnes N.

Respir Res. 2019 Aug 23;20(1):195. doi: 10.1186/s12931-019-1157-0.

4.

Co-carcinogenic effects of vitamin E in prostate.

Vivarelli F, Canistro D, Cirillo S, Papi A, Spisni E, Vornoli A, Croce CMD, Longo V, Franchi P, Filippi S, Lucarini M, Zanzi C, Rotondo F, Lorenzini A, Marchionni S, Paolini M.

Sci Rep. 2019 Aug 12;9(1):11636. doi: 10.1038/s41598-019-48213-1.

5.

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA.

Albers FC, Papi A, Taillé C, Bratton DJ, Bradford ES, Yancey SW, Kwon N.

Respir Res. 2019 Jul 30;20(1):169. doi: 10.1186/s12931-019-1134-7.

6.

Right Ventricle Function in Patients with Acute Coronary Syndrome and Concomitant Undiagnosed Chronic Obstructive Pulmonary Disease.

Pavasini R, Fiorencis A, Tonet E, Gaudenzi E, Balla C, Maietti E, Biscaglia S, Papi A, Ferrari R, Contoli M, Campo G.

COPD. 2019 Jul 29:1-8. doi: 10.1080/15412555.2019.1645105. [Epub ahead of print]

PMID:
31357891
7.

Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.

Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D.

Lancet Respir Med. 2019 Sep;7(9):745-756. doi: 10.1016/S2213-2600(19)30190-0. Epub 2019 Jul 4.

PMID:
31281061
8.

Airway inflammatory profile is correlated with symptoms in stable COPD: A longitudinal proof-of-concept cohort study.

Contoli M, Baraldo S, Conti V, Gnesini G, Marku B, Casolari P, Scrigner P, Morelli P, Saetta M, Spanevello A, Papi A.

Respirology. 2019 Jun 28. doi: 10.1111/resp.13607. [Epub ahead of print]

PMID:
31251440
9.

IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis.

Starkey MR, Plank MW, Casolari P, Papi A, Pavlidis S, Guo Y, Cameron GJM, Haw TJ, Tam A, Obiedat M, Donovan C, Hansbro NG, Nguyen DH, Nair PM, Kim RY, Horvat JC, Kaiko GE, Durum SK, Wark PA, Sin DD, Caramori G, Adcock IM, Foster PS, Hansbro PM.

Eur Respir J. 2019 Jul 18;54(1). pii: 1800174. doi: 10.1183/13993003.00174-2018. Print 2019 Jul.

PMID:
31196943
10.

Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.

Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, Pavord ID, Williams M, Weatherall M; Novel START Study Team.

N Engl J Med. 2019 May 23;380(21):2020-2030. doi: 10.1056/NEJMoa1901963. Epub 2019 May 19.

PMID:
31112386
11.

Benralizumab for the Prevention of COPD Exacerbations.

Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA and TERRANOVA Study Investigators; GALATHEA Study Investigators; TERRANOVA Study Investigators.

N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20.

PMID:
31112385
12.

Asthma progression and mortality: the role of inhaled corticosteroids.

O'Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P.

Eur Respir J. 2019 Jul 18;54(1). pii: 1900491. doi: 10.1183/13993003.00491-2019. Print 2019 Jul. Review.

13.

Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations.

Papi A, Petruzzelli S, Vezzoli S, Georges G, Fabbri LM.

Eur Respir J. 2019 Apr 18;53(4). pii: 1900147. doi: 10.1183/13993003.00147-2019. Print 2019 Apr. No abstract available.

PMID:
31000665
14.

Epigallocatechin-3-gallate inhibits doxorubicin-induced inflammation on human ovarian tissue.

Fabbri R, Macciocca M, Vicenti R, Caprara G, Piccinni MP, Paradisi R, Terzano P, Papi A, Seracchioli R.

Biosci Rep. 2019 May 14;39(5). pii: BSR20181424. doi: 10.1042/BSR20181424. Print 2019 May 31.

15.

Letter from Italy.

Papi A.

Respirology. 2019 Jun;24(6):605-606. doi: 10.1111/resp.13554. Epub 2019 Apr 8. No abstract available.

16.

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.

Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 28;14:531-546. doi: 10.2147/COPD.S196383. eCollection 2019.

17.

Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study.

Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, Singh D, Nicolini G, Kraft M; ATLANTIS study group.

Lancet Respir Med. 2019 May;7(5):402-416. doi: 10.1016/S2213-2600(19)30049-9. Epub 2019 Mar 12. Erratum in: Lancet Respir Med. 2019 Sep;7(9):e28.

PMID:
30876830
18.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 May 18;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May. Review.

PMID:
30846476
19.

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation.

Singh D, Fabbri LM, Corradi M, Georges G, Guasconi A, Vezzoli S, Petruzzelli S, Papi A.

Eur Respir J. 2019 May 18;53(5). pii: 1900235. doi: 10.1183/13993003.00235-2019. Print 2019 May. No abstract available.

PMID:
30792343
20.

Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study.

Papi A, Zheng J, Criner GJ, Fabbri LM, Calverley PMA.

Respir Med. 2019 Feb;147:37-43. doi: 10.1016/j.rmed.2018.12.014. Epub 2019 Jan 9.

PMID:
30704697
21.

Genomic stability, anti-inflammatory phenotype, and up-regulation of the RNAseH2 in cells from centenarians.

Storci G, De Carolis S, Papi A, Bacalini MG, Gensous N, Marasco E, Tesei A, Fabbri F, Arienti C, Zanoni M, Sarnelli A, Santi S, Olivieri F, Mensà E, Latini S, Ferracin M, Salvioli S, Garagnani P, Franceschi C, Bonafè M.

Cell Death Differ. 2019 Sep;26(9):1845-1858. doi: 10.1038/s41418-018-0255-8. Epub 2019 Jan 8.

PMID:
30622304
22.

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.

Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 12;13:3971-3981. doi: 10.2147/COPD.S185975. eCollection 2018. Review.

23.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
24.

Differential expression of RNA-binding proteins in bronchial epithelium of stable COPD patients.

Ricciardi L, Col JD, Casolari P, Memoli D, Conti V, Vatrella A, Vonakis BM, Papi A, Caramori G, Stellato C.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 12;13:3173-3190. doi: 10.2147/COPD.S166284. eCollection 2018.

25.

Blood eosinophils for the management of COPD patients?

Fabbri LM, Beghé B, Papi A.

Lancet Respir Med. 2018 Nov;6(11):807-808. doi: 10.1016/S2213-2600(18)30417-X. Epub 2018 Oct 18. No abstract available.

PMID:
30343030
26.

Inhaled triple therapy in chronic obstructive pulmonary disease - Authors' reply.

Papi A, Singh D, Petruzzelli S, Guasconi A, Vestbo J.

Lancet. 2018 Sep 29;392(10153):1113-1114. doi: 10.1016/S0140-6736(18)31778-1. No abstract available.

PMID:
30303077
27.

Effects of Anti-IL-5 on Virus-induced Exacerbation in Asthma. Light and Shadow.

Contoli M, Papi A.

Am J Respir Crit Care Med. 2019 Feb 15;199(4):410-411. doi: 10.1164/rccm.201809-1684ED. No abstract available.

PMID:
30265568
28.

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study.

Ferguson GT, Papi A, Anzueto A, Kerwin EM, Cappelletti C, Duncan EA, Nyberg J, Dorinsky P.

Eur Respir J. 2018 Sep 16;52(3). pii: 1801334. doi: 10.1183/13993003.01334-2018. Print 2018 Sep.

29.

Inhaled corticosteroid containing combinations and mortality in COPD.

Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A, Vezzoli S, Singh D.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801230. doi: 10.1183/13993003.01230-2018. Print 2018 Dec. No abstract available.

PMID:
30209195
30.

Inhaled corticosteroids in COPD: friend or foe?

Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, Rabe KF, Papi A.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801219. doi: 10.1183/13993003.01219-2018. Print 2018 Dec. Review.

PMID:
30190269
31.

Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro.

Farabegoli F, Govoni M, Spisni E, Papi A.

Nutrients. 2018 Aug 22;10(9). pii: E1141. doi: 10.3390/nu10091141.

32.

Diffuse pulmonary meningothelial like nodules simulating metastatic thymoma.

Tamburini N, Morandi L, Rinaldi R, Maniscalco P, Quarantotto F, Montinari E, Papi A, Anania G, Cavallesco G.

J Thorac Dis. 2018 Jun;10(6):E442-E446. doi: 10.21037/jtd.2018.05.178. No abstract available.

33.

Clinical and Pathologic Factors Predicting Future Asthma in Wheezing Children. A Longitudinal Study.

Bonato M, Bazzan E, Snijders D, Tinè M, Biondini D, Turato G, Balestro E, Papi A, Cosio MG, Barbato A, Baraldo S, Saetta M.

Am J Respir Cell Mol Biol. 2018 Oct;59(4):458-466. doi: 10.1165/rcmb.2018-0009OC.

PMID:
29812990
34.

Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD.

Santus P, Radovanovic D, Mascetti S, Pauletti A, Valenti V, Mantero M, Papi A, Contoli M.

Pharmacol Res. 2018 Jul;133:160-169. doi: 10.1016/j.phrs.2018.05.010. Epub 2018 May 23.

PMID:
29775687
35.

The anti-proliferative and anti-inflammatory response of COPD airway smooth muscle cells to hydrogen sulfide.

Perry MM, Tildy B, Papi A, Casolari P, Caramori G, Rempel KL, Halayko AJ, Adcock I, Chung KF.

Respir Res. 2018 May 9;19(1):85. doi: 10.1186/s12931-018-0788-x.

36.

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A.

Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3.

37.

Efficacy and safety profile of xanthines in COPD: a network meta-analysis.

Cazzola M, Calzetta L, Barnes PJ, Criner GJ, Martinez FJ, Papi A, Gabriella Matera M.

Eur Respir Rev. 2018 May 2;27(148). pii: 180010. doi: 10.1183/16000617.0010-2018. Print 2018 Jun 30. Review.

38.

Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations.

Zhu J, Message SD, Mallia P, Kebadze T, Contoli M, Ward CK, Barnathan ES, Mascelli MA, Kon OM, Papi A, Stanciu LA, Edwards MR, Jeffery PK, Johnston SL.

J Allergy Clin Immunol. 2019 Jan;143(1):114-125.e4. doi: 10.1016/j.jaci.2018.04.003. Epub 2018 Apr 24.

39.

Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma.

Papi A, Ryan D, Soriano JB, Chrystyn H, Bjermer L, Rodríguez-Roisin R, Dolovich MB, Harris M, Wood L, Batsiou M, Thornhill SI, Price DB.

J Allergy Clin Immunol Pract. 2018 Nov - Dec;6(6):1989-1998.e3. doi: 10.1016/j.jaip.2018.03.008. Epub 2018 Apr 5.

PMID:
29627457
40.

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.

Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D.

Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Erratum in: Lancet. 2018 Feb 26;:.

PMID:
29429593
41.

Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?

Wilson KC, Krishnan JA, Sliwinski P, Criner GJ, Miravitlles M, Hurst JR, Calverley PMA, Albert RK, Rigau D, Tonia T, Vestbo J, Papi A, Rabe KF, Anzueto A, Wedzicha JA.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702577. doi: 10.1183/13993003.02577-2017. Print 2018 Jan. No abstract available.

42.

TGF-β Signaling Pathways in Different Compartments of the Lower Airways of Patients With Stable COPD.

Di Stefano A, Sangiorgi C, Gnemmi I, Casolari P, Brun P, Ricciardolo FLM, Contoli M, Papi A, Maniscalco P, Ruggeri P, Girbino G, Cappello F, Pavlides S, Guo Y, Chung KF, Barnes PJ, Adcock IM, Balbi B, Caramori G.

Chest. 2018 Apr;153(4):851-862. doi: 10.1016/j.chest.2017.12.017. Epub 2017 Dec 28.

43.

Asthma.

Papi A, Brightling C, Pedersen SE, Reddel HK.

Lancet. 2018 Feb 24;391(10122):783-800. doi: 10.1016/S0140-6736(17)33311-1. Epub 2017 Dec 19. Review.

PMID:
29273246
44.

Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal.

Hillyer EV, Price DB, Chrystyn H, Martin RJ, Israel E, van Aalderen WMC, Papi A, Usmani OS, Roche N.

J Aerosol Med Pulm Drug Deliv. 2018 Apr;31(2):111-113. doi: 10.1089/jamp.2017.1396. Epub 2017 Nov 28. No abstract available.

45.

The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.

Singh D, Vezzoli S, Petruzzelli S, Papi A.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 3;12:3263-3271. doi: 10.2147/COPD.S141416. eCollection 2017.

46.

Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study.

Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR.

Am J Respir Crit Care Med. 2018 May 1;197(9):1223-1226. doi: 10.1164/rccm.201709-1822LE. No abstract available.

PMID:
29099609
47.

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.

Singh D, Corradi M, Spinola M, Papi A, Usmani OS, Scuri M, Petruzzelli S, Vestbo J.

Int J Chron Obstruct Pulmon Dis. 2017 Oct 6;12:2917-2928. doi: 10.2147/COPD.S146822. eCollection 2017. Review.

48.

We Have to Learn to Do without Knowing Enough: Antieosinophilic Treatments for Severe Asthma.

Papi A, Beghé B, Fabbri LM.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):1-2. doi: 10.1164/rccm.201710-1970ED. No abstract available.

PMID:
29043835
49.

Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD.

Contoli M, Pauletti A, Rossi MR, Spanevello A, Casolari P, Marcellini A, Forini G, Gnesini G, Marku B, Barnes N, Rizzi A, Curradi G, Caramori G, Morelli P, Papi A.

Eur Respir J. 2017 Oct 5;50(4). pii: 1700451. doi: 10.1183/13993003.00451-2017. Print 2017 Oct.

50.

Endothelial dysfunction and increased platelet reactivity in patients with acute coronary syndrome and undiagnosed COPD: insights into the SCAP trial.

Pavasini R, Vieceli Dalla Sega F, Gallo F, Passarini G, Papi A, Contoli M, Campo G.

Eur Respir J. 2017 Oct 5;50(4). pii: 1701183. doi: 10.1183/13993003.01183-2017. Print 2017 Oct. No abstract available.

Supplemental Content

Support Center